Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Jul;97(Suppl 1):11–15.

Intravenous immune globulin in primary immunodeficiency.

M Haeney 1
PMCID: PMC1550367  PMID: 8033427

Abstract

The development of safe and effective intravenous preparations of immune globulin (IVIG) represents a major advance in the treatment of patients with severe antibody deficiencies. Such therapy is expensive, few trials have been performed to compare one type of IVIG preparation with another under equivalent conditions, and published studies have been of relatively short duration. The overall consensus is that high-dose IVIG (at least 400/mg/kg/month) is superior to lower doses and most clinicians aim to maintain trough IgG levels above an arbitrary level of 5 g/l. Adverse reactions, usually mild, are common in antibody-deficient patients during the first few infusions, but severe, anaphylactoid reactions are extremely rare other than in patients with antibodies to IgA. IVIG is not associated with transmission of human immunodeficiency virus or hepatitis B, but there remains a small but definite risk of transmission of non-A, non-B hepatitis, including hepatitis C. Self-infusion of IVIG in the patient's home is a realistic alternative to hospitalization. In the UK, guidelines for home therapy have been approved by professional medical bodies and by the Department of Health. Home therapy has proven to be both safe and cost-effective.

Full text

PDF
15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ammann A. J., Ashman R. F., Buckley R. H., Hardie W. R., Krantmann H. J., Nelson J., Ochs H., Stiehm E. R., Tiller T., Wara D. W. Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol. 1982 Jan;22(1):60–67. doi: 10.1016/0090-1229(82)90022-8. [DOI] [PubMed] [Google Scholar]
  2. Ashida E. R., Saxon A. Home intravenous immunoglobulin therapy by self-administration. J Clin Immunol. 1986 Jul;6(4):306–309. doi: 10.1007/BF00917331. [DOI] [PubMed] [Google Scholar]
  3. Bernatowska E., Madaliński K., Janowicz W., Weremowicz R., Gutkowski P., Wolf H. M., Eibl M. M. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin Immunol Immunopathol. 1987 May;43(2):153–162. doi: 10.1016/0090-1229(87)90123-1. [DOI] [PubMed] [Google Scholar]
  4. Björkander J., Bake B., Hanson L. A. Primary hypogammaglobulinaemia: impaired lung function and body growth with delayed diagnosis and inadequate treatment. Eur J Respir Dis. 1984 Oct;65(7):529–536. [PubMed] [Google Scholar]
  5. Björkander J., Cunningham-Rundles C., Lundin P., Olsson R., Söderström R., Hanson L. A. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med. 1988 Jan;84(1):107–111. doi: 10.1016/0002-9343(88)90016-2. [DOI] [PubMed] [Google Scholar]
  6. Björkander J., Hammarström L., Smith C. I., Buckley R. H., Cunningham-Rundles C., Hanson L. A. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol. 1987 Jan;7(1):8–15. doi: 10.1007/BF00915419. [DOI] [PubMed] [Google Scholar]
  7. Blore J., Haeney M. R. Primary antibody deficiency and diagnostic delay. BMJ. 1989 Feb 25;298(6672):516–517. doi: 10.1136/bmj.298.6672.516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Buckley R. H., Schiff R. I. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 1991 Jul 11;325(2):110–117. doi: 10.1056/NEJM199107113250207. [DOI] [PubMed] [Google Scholar]
  9. Burks A. W., Sampson H. A., Buckley R. H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med. 1986 Feb 27;314(9):560–564. doi: 10.1056/NEJM198602273140907. [DOI] [PubMed] [Google Scholar]
  10. Casteels-Van Daele M., Wijndaele L., Hanninck K., Gillis P. Intravenous immune globulin and acute aseptic meningitis. N Engl J Med. 1990 Aug 30;323(9):614–615. [PubMed] [Google Scholar]
  11. Chapel H. M. Consensus on diagnosis and management of primary antibody deficiencies. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies. BMJ. 1994 Feb 26;308(6928):581–585. doi: 10.1136/bmj.308.6928.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chapel H., Brennan V., Delson E. Immunoglobulin replacement therapy by self-infusion at home. Clin Exp Immunol. 1988 Jul;73(1):160–162. [PMC free article] [PubMed] [Google Scholar]
  13. Cochrane S., Haeney M. R. Self-induced "buzz" achieved by rapid infusion of immunoglobulin. Lancet. 1990 Jul 14;336(8707):123–124. doi: 10.1016/0140-6736(90)91645-q. [DOI] [PubMed] [Google Scholar]
  14. Cunningham-Rundles C. Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol. 1989 Jan;9(1):22–33. doi: 10.1007/BF00917124. [DOI] [PubMed] [Google Scholar]
  15. Cunningham-Rundles C., Siegal F. P., Smithwick E. M., Lion-Boulé A., Cunningham-Rundles S., O'Malley J., Barandun S., Good R. A. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984 Oct;101(4):435–439. doi: 10.7326/0003-4819-101-4-435. [DOI] [PubMed] [Google Scholar]
  16. Gardulf A., Hammarström L., Smith C. I. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991 Jul 20;338(8760):162–166. doi: 10.1016/0140-6736(91)90147-h. [DOI] [PubMed] [Google Scholar]
  17. Hermaszewski R. A., Webster A. D. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med. 1993 Jan;86(1):31–42. [PubMed] [Google Scholar]
  18. Hill L. E., Mollison P. L. Hypogammaglobulinaemia in the United Kigdom. 13. Conclusions. Spec Rep Ser Med Res Counc (G B) 1971;310:124–127. [PubMed] [Google Scholar]
  19. Jefferis R., Kumararatne D. S. Selective IgG subclass deficiency: quantification and clinical relevance. Clin Exp Immunol. 1990 Sep;81(3):357–367. doi: 10.1111/j.1365-2249.1990.tb05339.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lederman H. M., Winkelstein J. A. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985 May;64(3):145–156. [PubMed] [Google Scholar]
  21. Lever A. M., Webster A. D., Brown D., Thomas H. C. Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet. 1984 Nov 10;2(8411):1062–1064. doi: 10.1016/s0140-6736(84)91506-x. [DOI] [PubMed] [Google Scholar]
  22. Lundblad J. L., Londeree N., Mitra G. Characterisation of various intravenous immunoglobulin preparations. J Infect. 1987 Jul;15 (Suppl 1):3–12. doi: 10.1016/s0163-4453(87)92414-5. [DOI] [PubMed] [Google Scholar]
  23. Mankarious S., Lee M., Fischer S., Pyun K. H., Ochs H. D., Oxelius V. A., Wedgwood R. J. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med. 1988 Nov;112(5):634–640. [PubMed] [Google Scholar]
  24. Misbah S. A., Chapel H. M. Adverse effects of intravenous immunoglobulin. Drug Saf. 1993 Oct;9(4):254–262. doi: 10.2165/00002018-199309040-00003. [DOI] [PubMed] [Google Scholar]
  25. Montanaro A., Pirofsky B. Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am J Med. 1984 Mar 30;76(3A):67–72. doi: 10.1016/0002-9343(84)90322-x. [DOI] [PubMed] [Google Scholar]
  26. Nolte M. T., Pirofsky B., Gerritz G. A., Golding B. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol. 1979 May;36(2):237–243. [PMC free article] [PubMed] [Google Scholar]
  27. Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet. 1985 Feb 16;1(8425):404–405. [PubMed] [Google Scholar]
  28. Ochs H. D., Lee M. L., Fischer S. H., Delson E. S., Chang B. S., Wedgwood R. J. Self-infusion of intravenous immunoglobulin by immunodeficient patients at home. J Infect Dis. 1987 Oct;156(4):652–654. doi: 10.1093/infdis/156.4.652. [DOI] [PubMed] [Google Scholar]
  29. Roifman C. M., Lederman H. M., Lavi S., Stein L. D., Levison H., Gelfand E. W. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med. 1985 Aug;79(2):171–174. doi: 10.1016/0002-9343(85)90006-3. [DOI] [PubMed] [Google Scholar]
  30. Roifman C. M., Levison H., Gelfand E. W. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987 May 9;1(8541):1075–1077. doi: 10.1016/s0140-6736(87)90494-6. [DOI] [PubMed] [Google Scholar]
  31. Römer J., Morgenthaler J. J., Scherz R., Skvaril F. Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang. 1982 Feb;42(2):62–73. doi: 10.1159/000460850. [DOI] [PubMed] [Google Scholar]
  32. Schiff R. I., Sedlak D., Buckley R. H. Rapid infusion of Sandoglobulin in patients with primary humoral immunodeficiency. J Allergy Clin Immunol. 1991 Jul;88(1):61–67. doi: 10.1016/0091-6749(91)90301-4. [DOI] [PubMed] [Google Scholar]
  33. Sneller M. C., Strober W., Eisenstein E., Jaffe J. S., Cunningham-Rundles C. NIH conference. New insights into common variable immunodeficiency. Ann Intern Med. 1993 May 1;118(9):720–730. doi: 10.7326/0003-4819-118-9-199305010-00011. [DOI] [PubMed] [Google Scholar]
  34. Sorensen R. U., Polmar S. H. Efficacy and safety of high-dose intravenous immune globulin therapy for antibody deficiency syndromes. Am J Med. 1984 Mar 30;76(3A):83–90. doi: 10.1016/0002-9343(84)90325-5. [DOI] [PubMed] [Google Scholar]
  35. Stiehm E. R. Human gamma globulins as therapeutic agents. Adv Pediatr. 1988;35:1–72. [PubMed] [Google Scholar]
  36. Waldmann T. A., Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1–110. doi: 10.1159/000385919. [DOI] [PubMed] [Google Scholar]
  37. Weiland O., Mattsson L., Glaumann H. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet. 1986 Apr 26;1(8487):976–977. doi: 10.1016/s0140-6736(86)91081-0. [DOI] [PubMed] [Google Scholar]
  38. Williams P. E., Yap P. L., Gillon J., Crawford R. J., Urbaniak S. J., Galea G. Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin. Vox Sang. 1989;57(1):15–18. doi: 10.1111/j.1423-0410.1989.tb04977.x. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES